 |
|
Foam Sclerotherapy
A New Era
Arch Dermatol. 2003;139:1494-1496.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
THE EUROPEAN dermatology community has long embraced phlebology. The systematic study of venous diseases among dermatologists in Europe has flourished since the 18th century. In contrast, dermatologists in the United States have mostly focused on the treatment of venous ulcers; only recently have sclerotherapy and surgical phlebology been slowly gaining prominence.1
The interest in sclerotherapy plateaued in the 1980s, as the state of the art stagnated. Then in 1993, Juan Cabrera, first author of the sclerotherapy article appearing in this issue of the ARCHIVES,2 began using a microfoam preparation of sodium tetradecyl sulfate and polidocanol for sclerotherapy. It represented a revolution in the treatment of venous diseases.2-3
The history of foam sclerotherapy actually dates back to Orbach,4 who first proposed the use of foam in 1944, generated by the simple process of shaking a sclerosant solution in a syringe with air. This produced a foam with large bubbles and a . . . [Full Text of this Article]
Te-Shao Hsu, MD
SkinCare Physicians of Chestnut Hill
1244 Boylston St, Suite 302
Chestnut Hill, MA 02467
Robert A. Weiss, MD
Hunt Valley, Md
RELATED ARTICLE
Treatment of Venous Malformations With Sclerosant in Microfoam Form
Juan Cabrera, Juan Cabrera, Jr, Ma Antonia García-Olmedo, and Pedro Redondo
Arch Dermatol. 2003;139(11):1409-1416.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The Hidden Face of Venous Malformations: A Multidisciplinary Therapeutic Approach
Redondo
Arch Dermatol 2008;144:922-926.
FULL TEXT
|
